|Mr. Mark A. Emalfarb||Founder, CEO, Pres & Director||918.05k||N/A||1956|
|Ms. Ping Wang Rawson||Chief Financial Officer||285.06k||N/A||1976|
|Mr. Matthew S. Jones||Managing Director of Bus. Devel. & Licensing||352.4k||N/A||1978|
|Dr. Ronen Tchelet||VP of Research & Bus. Devel.||248.84k||N/A||1958|
|Ms. Ana Gómez Rodriguez||Sec. of the Board||N/A||N/A||N/A|
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Dyadic International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.